At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 168 enrolled
Drug / intervention
Ramucirumab +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
In Brief
A Phase 2 clinical trial evaluating Ramucirumab, Placebo, and 3 other interventions for Stomach Cancer and Esophageal Cancer. Completed, enrolled 168 participants across 58 sites.
Detailed Summary
The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStomach Cancer, Esophageal Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartApr 2011
Primary CompletionSep 2013
Study CompletionMay 2014
TodayJul 2026
First PostedNov 24, 2010
Enrollment StartApr 1, 2011
Primary CompletionSep 1, 2013
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 15.6 years ago
Interventions
Ramucirumabbiological
Administered intravenously
Placebodrug
Administered intravenously
Oxaliplatindrug
Administered intravenously
Leucovorindrug
Administered intravenously
5-Fluorouracildrug
Administered intravenously